Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Honed my skills with high school students.
Incredible posts with details that everyone can understand. Well done and thank you!
I'll get paid; very handsomely.
falconer, they're not paying you enough...
Probably not, but....
...can 2-73 fix the FLNA/ scaffolding protein after its been altered?
Simufilam, the SAVA drug, and blarcamesine.
Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. Altered FLNA in the brain disrupts the normal function of neurons, leading to Alzheimer’s pathology, neurodegeneration and neuroinflammation.
But what could Dr. Hagerman know?
The authority of various commentators telling of Anavex drug safety and efficacy has quite frequently been brought into contention. The comments of Dr. Randi J. Hagerman have been quite supportive. But are they substantial, based upon knowledge and fact; or mere hope or ignorance?
Check what the UC Davis MIND Institute, part of the University of California Davis Medical School, posts about this medical professional:
https://health.ucdavis.edu/team/search/598/randi-hagerman---pediatric-child-development---behavior---autism---neurodevelopmental-disorders-sacramento
Clinical Interests
Dr. Hagerman's main areas of research are targeted treatment trials in Fragile X Syndrome (FXS), Rett Syndrome, Fragile X-associated Tremor/Ataxia Syndrome (FXTAS), and Autism Spectrum Disorder (ASD). Her clinical patients include: FXS, FXTAS, ASD, and other neurodevelopmental disorders.
Research/Academic Interests
Randi Hagerman, M.D., FAAP, is a Distinguished Professor of Pediatrics at the University of California Davis Medical Center and Director of the Fragile X Research and Treatment Center at the MIND Institute and holds an Endowed Chair in Fragile X Research. Dr. Hagerman is a developmental and behavioral pediatrician and has studied patients with fragile X syndrome (FXS), autism (ASD), and other neurodevelopmental disorders. She has carried out numerous targeted treatment studies in FXS and autism. She and her husband and team have published extensively regarding fragile X premutation disorders including the first description of FXTAS in 2001. She co-founded the National Fragile X Foundation in 1984 and has been involved in targeted treatments for fragile X syndrome, autism, and FXTAS for several years. Dr Hagerman has written over 400 peer-reviewed articles and several books on fragile X and autism. Her most recent books are R. Hagerman and R. Hendren (eds) (2014) Treatment of Neurodevelopmental Disorders: Targeting Neurobiological Mechanisms published by Oxford University Press and, E. Hollander, R. Hagerman and D. Fein (eds) (2018) Autism Spectrum Disorders, American Psychiatric Association Publishing; in 2020, two books including: 2nd Edition of Textbook of Autism Spectrum Disorders, E. Hollander, R. Hagerman and C. Ferretti (eds), American Psychiatric Publishing Inc. (APPI); and, Fragile X Syndrome and the Premutation: New Developments and Treatments, Hagerman RJ and Hagerman PJ, (eds), Mac Keith Press.
The population was 100% with Rett.
For neurodevelopmental disorders that affects a very small population.
Cellular complexities; their origins.
And if you get to the point where you are, in understanding, how do you explain how all this comes about when any two drunk or otherwise ignorant people can make a baby?
Who figured out what goes where and such?
Oops! My error.
That’s the closest I’ll ever get to understanding what goes on in the meteorkondrea.
But, protein folding is even more complex.
Nice, educational video on protein folding. Good intro; but incomplete.
It's claimed or implied that protein folding is solely dependent upon the particular sequence of amino acids in the protein. Doubtless, this a major, even requisite pre-condition. If the wrong amino acids get inserted or substituted, the protein will fold improperly. This is the mechanism of most mutations; a genetics, amino acid sequence problem.
But, in regard to blarcamesine (the Anavex drug) treating various central nervous system (CNS) diseases, which involve or are caused by mis-folded proteins (in most cases, reaction-controlling enzymes), the proteins (enzymes) don't mis-fold because of new genetic, amino acid sequence errors. The genes controlling protein synthesis in people with Alzheimer's disease are the same in childhood as in old age. No Alzheimer's in childhood; but the disease appears with age. Same genes, but waste-clearing proteins abundant in childhood are no longer produced. With age, the enzyme proteins that clear wastes in the neuron mis-fold, or fail to fold altogether. Normally-cleared metabolic wastes accumulate; neuron functions become ever more compromised.
The video failed to tell where protein folding occurs. Most of it happens in, is directed by the mitochondria. Chemical conditions in those organelles have to be just-so. Exactly the proper pH, with sufficient adenosine triphosphate (ATP) to provide the energy driving the folding reactions. Various minerals, particularly calcium ions, also have to be present and available in precise concentrations, at precise locations. If any of these protein folding factors are anomalous, the protein, an essential reaction-controlling enzyme, gets literally bent out of shape, and is thereby unable to catalyze its waste-clearing reactions. Wastes accumulate, one of the CNS diseases sets in.
In the neuron, blarcamesine, propitiously, binds to the sigma-1 receptor protein and causes it to function properly and effectively. Among other things, that restores the required, proper chemistry inside the attached mitochondria. Properly-shaped proteins can then, as in youth, be folded. Wastes, once again, can be cleared.
Good one. 'Green Swan' events.
...the charts are only back ward looking, have no way to factor in Green Swan events.
Adding that to my SNPW determining diligence!
If these panels are as good as it appears, we are a buyout candidate at a few billion $ for some company that has the infrastructure to mass produce.
Sun Power's big future is solar power.
...their patented solar panels are worth [at least] $187+ million per year...
When that happens....
Once we get the first one out [approval to sell and therapeutically use an Anavex drug,] attention-support will build.
Homeostasis forms. Blarcamesine at the top.
This referred-to posting, accurately, describes somatic (whole-body) and systemic (organ system) homeostatic processes.
But blarcamesine (Anavex 2-73) modulates or restores different kinds: intracellular (within a cell) and histological (within a tissue) homeostatic processes. When either of those are malfunctioning, things go wrong first in the involved cells, and then in the cells of the involved tissue. In the case of central nervous system diseases, blarcamesine restores various, important homeostatic processes within individual neurons, nerve cells. With that, nerves as tissues can function normally, preventing all sorts of "downstream" pathologic anomalies that result when neurons and nerves don't work right, when nerve and neuron homeostatic processes are disrupted.
No "fire."
Properly, pyrolytic processes involve no "fire" inside the reaction vessels. In crude systems (which is not at this facility) a flame (usually from natural gas combustion) is used to heat the materials being pyrolyzed.
But the key is this. In pyrolysis, the heated, processed materials do not combust or burn --- because no oxygen (or air) is allowed inside the sealed reaction vessel. The provided external heat, often along with certain un-consumed mineral or metallic catalysts, simply breaks down, "lyses," the materials being processed, In this case, it will be primarily the plastics in medical materials. Those are pyrolyzed to combustible gases (similar to methane, natural gas), which are completely combusted in the three power generator engines at the facility.
Pyrolytic heating is often from electrical elements, as in an electric oven.
But only upon ignition.
Beware, science and sarcasm are known to create an explosive gas when mixed, under certain conditions...
Imagine that. No interest. No knowledge.
There is no evidence that any biopharma companies are interested in Anavex. Not Eisai. Not Pfizer. Not Johnson & Johnson. And not Merck.
New phraseology: "Sigma-1 Receptor Pathology."
I think the thesis for 2-73 is that it addresses Sigma 1 receptor disease,...
Big market for the Vayu drones.
A major market will be the sale of camera-loaded drones to law enforcement agencies. Instead of trying to fly very expensive helicopters to monitor nefarious activities on the ground, properly-equipped drones, such as those Vayu will provide, can be quickly launched and controlled to closely monitor things from aloft. Lacking in current drones are the abilities to stay aloft for extended periods. Their batteries run out. With the ability to stay aloft for several hours, the new drones can replace manned aircraft for most law enforcement aerial surveillance uses.
How many police departments in the US might wish to acquire a few of the new drones? There about 18,000 police departments in the US.
https://usafacts.org/articles/police-departments-explained/
Thanks.
For some time I've been following the postings on this message board; which prompted me to take a small, initial SNPW position. I used only discretionary funds I could afford to lose. After all, SNPW is, right now at least, by every definition a penny stock (well, almost; $0.008 isn't quite a penny).
So, decided to ease into the equity. Bought some at less than $0.002, then some for just twice that. At today's close I have a 224% gain.
Just wish I would have bought a lot more at less than 2 cents. Satisfied, however. If and when SNPW trades in the dollars, I'll be grinning.
I won't be trading any of this. Gonna sit back and watch. This looks to be be, for me, a long-term, many-years investment. Best wishes to all who, also, got in early.
Thanks; it's what I'm good at.
Thank you for taking such a complicated subject and articulating it so that the common joe can understand its meaning.
Well, it's a -mab, monoclonal antibody.
...comment on difference of A2-73 MOA vs this new "treatment".
A better adjective for blarcamesine.
To help convey the powerful, unique abilities of blarcamesine to treat (or prevent) various CNS and other diseases, the drug has been said to be pluripotent. But, as previously noted, in biology this term is usually reserved to describe the ability of various stem or primal cells to go on and develop into a diversity of new cells and tissues. Blarcamesine does not (at least directly) produce such newly-differentiated cells or tissues.
But, it does produce a wide variety of "downstream" therapeutic outcomes, all of which are favorable. A good adjective for this would be to say that "blarcamesine evokes or produces propitious outcomes." As a therapy, the molecule is, indeed, propitious.
https://www.dictionary.com/browse/propitious
adjective
1 presenting favorable conditions; favorable:
propitious weather.
2 indicative of favor; auspicious:
propitious omens.
3 favorably inclined; disposed to bestow favors or forgive:
propitious gods.
For some, "pluripotent" means "magic bean."
Properly, pluripotent refers to the ability of a stem or other primal cell to go on to develop into a plurality of new cell types. Properly, a molecule cannot be "pluripotent." (Look up the definition.)
But some molecules, such as blarcamesine (Anavex 2-73) can produce a plurality of favorable therapeutic outcomes. Some, who are yet unconvinced of this for the Anavex drug, regard any such representation to be in the realm of the "magic bean" concept; where rather magically the simple drug fixes just a wide variety of disorders and physiologic anomalies. Not something most would invest in, at least until proper, accepted double-blind studies have confirmed both required safety and efficacies.
Understood. Those holding to a magic bean skepticism for blarcamesine are not yet confident in the drug's eventual approval for sales and therapeutic use(s). They patiently (well, sort of) wait for the publication of peer-reviewed results from the on-going clinical trials with blarcamesine. Well and good. Very conservative; prudent even.
Others, however (including myself), have scrutinized the abundance of data on blarcamesine, in both murines (lab rodents) and real human beings and have consequently decided to take AVXL positions (of various sizes) so as to maximize our eventual equity values. We've purchased our Anavex Life Sciences Corp shares at prices lower than today. Personally, my AVXL position has a cost basis of $3.88. Presently, I have a value gain of $43.17%. In a few years, my percentage gains will require three digits, for a lot more shares (now owned) than if I were to try to purchase them then.
Differing investment styles.
Go to 38:21.
On the video, Dr. Hagerman's discourse on Anavex 2-73 starts at 38:21.
Worth a look and listen.
Because; the science will prevail.
You are the rare poster who only seeks to contribute scientific analysis to this message board.
Me, one thing. Quite another for Dr. Hagerman.
If someone w/her in deep understanding of the universe of CNS diseases and adverse issues with drugs along w/ things that could possibly go wrong says , "I want to use it myself", then that is NOT YOUR EVERY DAY ENDORSEMENT.
No negative comments. All Positive.
I listened and watched Dr. Hagerman's entire presentation; of course with particular attention to her comments on "Anavex 2-73."
First, understand that she is a world-class medical researcher, at a world-class medical research institute. No one knows more about the neurochemistry involved in all of the nerve diseases she talked about.
Over time, she has professionally worked with Anavex 2-73 (blarcamesine), administering it to patients in her clinical studies. Might it be then presumed that she has, as others here have, closely examined all that is and can be known about blarcamesine? If there are any problems with the drug, such as obviating side effects, poor efficacies, etc. wouldn't she be aware of those?
Nope. Not a word or phrase expressing any cautions, skepticisms, reservations, or anything negative about the Anavex drug. Who should inquisitive readers believe? Some retired biology teacher (me), or Dr. Randi Hagerman? She said, affirmed virtually everything I've claimed for the drug.
Exactly as I expected. The unique, positive biology of blarcamesine is ever more evident; especially, now, to a renowned medical researcher who has seen and knows what it actually does in her clinical subjects with various neurodevelopmental pathologies.
Right from the horse's mouth, as it were.
Without sales, there is no "pie."
If the pie is now larger he may be quite happy with a smaller piece...
Have taken a position. Very pleased.
Eventually, dimes or dollars.
As I posted (in this referenced message over a week ago), on the basis of solid information presented on this board, I decided I'd take a small SNPW position. Took a few days for my funds to get to my broker, but was able to buy a few hundred thousand shares at $0.0017.
Have been watching the share prices since; am very pleased. A slow but solid increase. I like the trend lines I see, coupled with all of the prospects of the company attaining new or larger revenue streams in 2021.
Most likely I'll have my bank mail in to my brokerage another, larger check. As mentioned earlier, I'll take ever larger positions as the one I have increases in value. I'll watch the share prices closely, but presently I can see no reason to sell out on any major price pull-back. Those happen because of the games day-traders and trading algorithm programs play. But the underlying soundness of Sun Pacific Holding's business model is firm. I'm not a trader; prefer to buy into young, promising companies that demonstrate a real future, then hold for many years. For SNPW, that may be five or ten years out. Then, hope to be rewarded with dividends. The long-term approach. So far, everything I see with this company fits that perspective. Instead of fractional pennies, the share price will be rendered in dimes or dollars.
Clarification, please; the annual meeting.
I just skimmed the announcement of the annual meeting. There were references to some sort of reverse split action, or new authorized shares action, apparently to be voted on by shareholders.
Would someone clarify these issues? What, exactly, is being proposed? What should shareholders vote for or against? What differences would such actions result in?
I'm a biologist, can understand the arcane minutiae of cellular biology, etc. But this? Need some help.
The 2020 AVXL share price trend.
On December 31, 2019, AVXL closed at $2.59. On December 31, 2020, AVXL closed at $5.40.
For the year 2020, it was worth 208.49% more at the end of the year, compared to the start of the year.
If that trend would continue at that exact percentage, on the first day in 2022 AVXL will be worth $11.28.
But should Anavex Life Sciences Corp gain approval for sale and therapeutic use of blarcamesine in 2021 for any disease or condition, including the rare disease Rett syndrome, the AVXL share price will far exceed $11.28.
Thanks. Will take a position.
Thank you, just the info I needed. I'll now take a small SNPW position, understanding that Sun Pacific Holding Corp is a tiny penny-stock company (well, micro-penny, right now). Not a company I'd fork over thousands of dollars to speculate on. But if the company can bring to production any of the listed projects, its share price will increase nicely in a year or two.
As I have successfully done with a few other penny stocks, I'll take my small position, then follow corporate developments closely. Should Sun Pacific begin to attain useful revenues, with their pushing of increasing share prices, I'll go on to accumulate larger positions, attempting to successfully ride the share price ascent as it might unfold in the next year or two.
Thanks again for the helpful info. My best wishes to all for the new year. Those in the know, keep us posted.
Why SNPW?
I've been rather intermittently following the postings on SNPW here for some time. Now that Uncle Sam will be depositing a few dollars in my checking account, those, for me, will be discretionary.
Can anyone summarize, at least in moderate detail, the future of Sun Pacific Holding Corp? In summary, tell me why I should consider taking a small SNPW position. I'm not a trader; prefer to buy equities that in one or two years will appreciate organically, because of actually increasing corporate values.
Please tell. Why will SNPW appreciate in 2021. It's still not so clear.
My thanks.
Also, the many genotypes of HSP.
Another "rare" set of CNS diseases that blarcamesine will eventually prove to effectively treat are the many forms of Hereditary Spastic Paraplegia (HSP). Personally, I have a mild form of HSP; my legs are always stiff, from hyperexcited motor neurons in my spinal column that control the muscles in my legs. This is caused by insufficient gamma-aminobutyric acid (GABA) levels in those neurons. As shown in the girls with Rett, blarcamesine elevates, restores normalized concentrations of GABA; will be an effective treatment of HSP in most or all of its many forms.
Listened to the doctor. She agrees.
...you add the scientific analysis to the Anavex story
Again, the Anavex prophylaxis factor.
...there are an additional 50% who [are] on the verge of glaucoma.
Blarcamesine for cataracts?
If blarcamesine were to prove to be a useful, efficacious therapy for cataracts (disruption, loss of eye lens clarity or shape), how many patients in the US might benefit?
"In 2010, white Americans age 40 and older had the highest prevalence rate of cataract (18 percent) followed by black Americans (13 percent). Hispanic Americans had the lowest rates of cataract (12 percent)."
https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/cataract-data-and-statistics
Blarcamesine for glaucoma?
If blarcamesine were to prove to be a useful, efficacious therapy for glaucoma (excess pressure within the eye), how many patients in the US might benefit?
"It is estimated that over 3 million Americans have glaucoma but only half of those know they have it."
https://www.glaucoma.org/glaucoma/glaucoma-facts-and-stats.php
Anavex yet to appear in general news.
When the general market finds out instead of just the biotech cult following...many more shares will be snatched for long-term investments.